DrugPatentWatch Database Preview➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing
« Back to Dashboard
Fulranumab is an investigational drug.
There have been 4 clinical trials for Fulranumab. The most recent clinical trial was a Phase 3 trial, which was initiated on March 1st 2015.
The most common disease conditions in clinical trials are Osteoarthritis and [disabled in preview]. The leading clinical trial sponsors are Janssen Research & Development, LLC and [disabled in preview].
There are six US patents protecting this investigational drug and two hundred and ninety-six international patents.
Recent Clinical Trials for Fulranumab
|Study of Efficacy, Safety of Fulranumab Monotherapy for OA of Hip or Knee, PAI3003||Janssen Research & Development, LLC||Phase 3|
|Study of Efficacy, Safety of Fulranumab Adjunctive Use in OA of Hip or Knee, PAI3001||Janssen Research & Development, LLC||Phase 3|
|Study of Efficacy, Safety of Fulranumab Monotherapy for OA of Hip or Knee, PAI3002||Janssen Research & Development, LLC||Phase 3|
Top disease conditions for Fulranumab
Top clinical trial sponsors for Fulranumab
|Drugname||Patent Number||Patent Title||Patent Assignee||Estimated Expiration|
|Fulranumab||Start Trial||Nucleic acid comprising or coding for a histone stem-loop and a poly(A) sequence or a polyadenylation signal for increasing the expression of an encoded therapeutic protein||CureVac AG (Tubingen, DE)||Start Trial|
|Fulranumab||Start Trial||Binding-triggered transcriptional switches and methods of use thereof||The Regents of the University of California (Oakland, CA)||Start Trial|
|Fulranumab||Start Trial||Cell culture medium||LA JOLLA BIOLOGICS, INC. (San Diego, CA)||Start Trial|
|>Drugname||>Patent Number||>Patent Title||>Patent Assignee||>Estimated Expiration|
|Drugname||Country||Document Number||Estimated Expiration||Related US Patent|
|>Drugname||>Country||>Document Number||>Estimated Expiration||>Related US Patent|